ConductScience.org, home

Paper30799404

Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options.

Ahrens M and 4 others. Oncol Res Treat, 2019. Cited by 43 papers, by iCite.

Cite this record

ConductScience Library. Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options. Papers, record 30799404. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30799404

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options.
PubMed
Journal
Oncol Res Treat
PubMed
Year
2019
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
43
iCite
Relative citation ratio, by iCite
1.49
iCite
Revised in PubMed
2019-08-19
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ahrens MMarit
2Scheich SSebastian
3Hartmann AArndt
4Bergmann LLothar
5IAG-N Interdisciplinary Working Group Kidney Cancer of the German Cancer SocietyGroup

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Agents, ImmunologicalMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Carcinoma, Renal CellMajor topic
KidneyMajor topic
Kidney NeoplasmsMajor topic
Costimulatory and Inhibitory T-Cell Receptors
Humans
Progression-Free Survival
Randomized Controlled Trials as Topic

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03075423Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCCBackground

Source ClinicalTrials.gov

Download CSV of trials

Cited by27

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 43 citations.

PMIDTitleJournalYearIn PapersSource
41294834Recent Advances in nccRCC Classification and Therapeutic Approaches.Cells2025https://conductscience.org/library/papers/41294834PubMed
40895976Oncological Outcomes of Non-clear Cell Renal Cell Carcinomas: A Retrospective Study From a Tertiary Care Center.Cureus2025https://conductscience.org/library/papers/40895976PubMed
40677703Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions.Front Immunol2025https://conductscience.org/library/papers/40677703PubMed
40660314Kinesin-related genes stratified the prognosis and immune responses of clear cell renal cell carcinoma.Eur J Med Res2025https://conductscience.org/library/papers/40660314PubMed
39743997Effectiveness of systemic treatments for advanced non-clear cell renal cell carcinoma: a systematic review and meta-analysis.Front Oncol2024https://conductscience.org/library/papers/39743997PubMed
39707614Exploiting NRF2-ARE pathway activation in papillary renal cell carcinoma.Int J Cancer2025https://conductscience.org/library/papers/39707614PubMed
39589483[Non-clear cell renal cell carcinoma].Urologie2024https://conductscience.org/library/papers/39589483PubMed
39512820Long non-coding RNAs: regulators of autophagy and potential biomarkers in therapy resistance and urological cancers.Front Pharmacol2024https://conductscience.org/library/papers/39512820PubMed
39252678Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.Health Technol Assess2024https://conductscience.org/library/papers/39252678PubMed
38434237The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma.Ther Adv Urol2024https://conductscience.org/library/papers/38434237PubMed
37849802The stratification and prognostic importance of molecular and immune landscapes in clear cell renal cell carcinoma.Front Oncol2023https://conductscience.org/library/papers/37849802PubMed
37686629Advanced Non-Clear Cell Renal Cell Carcinoma Treatments and Survival: A Real-World Single-Centre Experience.Cancers (Basel)2023https://conductscience.org/library/papers/37686629PubMed
37455214Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808.Clin Genitourin Cancer2023https://conductscience.org/library/papers/37455214PubMed
36661719Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature.Curr Oncol2023https://conductscience.org/library/papers/36661719PubMed
36275783Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy.Cancer Manag Res2022https://conductscience.org/library/papers/36275783PubMed
36238848miR-5590-3p inhibits the proliferation and metastasis of renal cancer cells by targeting ROCK2 to inhibit proliferation, migration and invasion.Oncol Lett2022https://conductscience.org/library/papers/36238848PubMed
35326557Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future.Cancers (Basel)2022https://conductscience.org/library/papers/35326557PubMed
35223991CircRNAs as Novel Biomarkers and Therapeutic Targets in Renal Cell Carcinoma.Front Mol Biosci2022https://conductscience.org/library/papers/35223991PubMed
35210307Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.J Immunother Cancer2022https://conductscience.org/library/papers/35210307PubMed
35061242Immune checkpoint inhibitor-associated myocarditis : Case reports and a review of the literature.Neth Heart J2022https://conductscience.org/library/papers/35061242PubMed

See all 27 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
MTOR2475PubTator's text mininghttps://conductscience.org/library/genes/2475NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30799404

GET https://conductscience.org/api/papers/v1/30799404/cited_by?page=2